Diabetes Journal Club March 17, 2011

Slides:



Advertisements
Similar presentations
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Advertisements

Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
Valsartan Antihypertensive Long-Term Use Evaluation Results
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2010.
Henry C. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Blood glucose: is lower better for diabetic patients?
Individualizing Targets and Tactics for High- Risk Patients With Type 2 Diabetes Practical lessons from ACCORD and other cardiovascular trials Featured.
ONTARGET Risk factors and outcomes associated with nonadherence Background ONTARGET compared the efficacy of the ARB telmisartan, the ACE inhibitor ramipril,
Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN For The ACCORD Study Group.
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
R1 강민혜 / prof. 전숙. Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.
R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.
Clinical Outcomes with Newer Antihyperglycemic Agents
Antonio Coca, MD, PhD, FRCP, FESC
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Blood Pressure and Lipid Trials: Rationale, Importance and Design
What should the Systolic BP treatment goal be in patients with CKD?
Clinical Outcomes with Newer Antihyperglycemic Agents
Nephrology Journal Club The SPRINT Trial Parker Gregg
The ACCORD Trial: Review of Design and Results
ACCORD Design and Baseline Characteristics
Title slide.
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Presented at the American Diabetes Association
Hypertension in the Post SPRINT era
Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study
LEADER trial: Primary Outcome
Recent Breakthroughs in Cardiovascular Outcomes Trials in T2DM
Clinical need for determination of vulnerable plaques
New Insights from EXSCEL
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
TNT: Baseline and final LDL cholesterol levels
Teaching Tool: Blood Pressure Classification
RAAS Blockade: Focus on ACEI
Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.
Systolic Blood Pressure Intervention Trial (SPRINT)
Diabetes Journal Club January 19, 2012 Margaux Añel-Tiangco, MD
CV Outcome Studies Empa-reg Leader Pio Stroke (Proactive) Bromocriptine Metformin-UKPDS.
The Hypertension in the Very Elderly Trial (HYVET)
LIFE: Reduction in primary end-point events seen with reduction of LVH by two electrocardiographic criteria End point % reduction with each 1050-mm x ms.
Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes.
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
CV Risk Management in T2DM: What Did We Learn from ADA 2016?
ASCOT-BPLA: Primary and secondary end points
APEX: Primary Efficacy and Safety Results
Screening, Lipid Stabilization, and Placebo Run-in
ARISE Trial Aggressive Reduction of Inflammation Stops Events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Comparison of Baseline Characteristics by Primary End Point
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%
FIELD: Primary outcome
Presentation transcript:

Diabetes Journal Club March 17, 2011 Margaux Añel-Tiangco, MD

Background ACCORD Cohort of 10,250 adults Mean age 62 Action to Control Cardiovascular Risk in Diabetes Cohort of 10,250 adults Mean age 62 Median DM duration of 10 years A1c ≥ 7.5% At high risk for CV disease Known CVD or two risk factors in addition to DM Assigned to: Intensive treatment: A1c <6% Standard treatment: A1c 7-7.9%

Background In 2008, the intensive treatment arm was stopped due to total and CV deaths (HR 1.22, 9% CI 1.01-1.46) On an average of 3.7 years, there was an excess of 3 deaths per 1000 subjects in the intensive tx arm No cause for excess mortality was found Not from increased hypoglycemia Not from a specific medication or combination of meds

Methods Intensive treatment arm was managed like the Standard treatment arm after year 3.7 Goal A1c 7-7.9% Pts were followed till year 5

Results By the final visit, both groups were similar in numbers of pts on oral agents, insulin, and their combinations Rates of severe hypoglycemia and other adverse events within the two groups were similar after the transition

Kaplan-Meier Curves Primary outcome: composite of nonfatal MI, nonfatal stroke, or death from CV causes

Hazard Ratios for the Prespecified Primary and Secondary Outcomes

Causes of Death

Incident Event Rates after the Transition Date

Conclusion Intensive DM therapy to A1c <6% did NOT decrease major CV events after 5 years and even led to more deaths than achieving an A1c 7-7.9%

Discussion Unclear reasons for mortality Equivalent rates of hypoglycemia in the post-transition period Degree of reduction in A1c cannot be implicated Those is intensive therapy were on multiple drug combos not used in standard therapy group 42% of pts were on ≥ 3 oral agents ± insulin Compared with only 19% of pts in the standard therapy

Discussion Results may not be applicable to those with newly diagnosed DM Holman et al. NEJM 2008; 359:1577-89 Newly dx DM Type 2 with normal goal A1c, median A1c 7% Neutral CV effect after 10 yrs  MI and death after 20 years